Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: Generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin

Clinical and Experimental Immunology

Volumn 108, Issue 2, 1997, Pages 333-339

  Blank, M ^a,b   Cines, D B ^c   Arepally, G ^c   Eldor, A ^b,d   Afek, A ^a   Shoenfeld, Y ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Faculty of Engineering   (Israel)

Author keywords

anti cardiolipin; anti endothelial cell antibody; anti PF4 heparin low molecular; Heparin induced; thrombocytopenia; weight heparin

Indexed keywords

CARDIOLIPIN ANTIBODY; DNA ANTIBODY; HEPARIN; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; THROMBOCYTE FACTOR 4;

ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; HEPARINIZATION; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS; VASCULITIS;

EID: 0030957259     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.d01-1008.x     Document Type: Article

References (52)

1. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958; 76:219-27.
2. Robert S, Bo FE, Rosato BFE, Rosato EF. Heparin: a cause of arterial emboli? Surgery (St. Louis) 1964; 55:803-8.
3. Chong BH. Heparin-incluced thrombocytopenia. (Review.) Brit J Heamatol 1995; 89:431-9.
4. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemostasis Thromb 1991; 10:1-34.
5. Edson JR. Heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120:355-6.
6. Green D, Harris K, Reynolds N, Roberts M, Patterson R. Heparin immune thrombocytopenia: evidence for heparin-platelet complex as the antigenic determinant. J Lab Clin Med 1978; 91:167-75.
7. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93:81-88.
8. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992; 67:545-9.
9. Zhang X, Chen L, Bancroft DP. Crystal structure of recombinant human platelet factor 4. Biochemistry 1994; 33:8361-6.
10. Stuckey JA, St Charles R, Edwards BFP. A model of the platelet factor 4 complex with heparin. In: Proteins: structure, function and genetics. Wiley-Liss, Inc., 1992; 14:277-87.
11. Furie BC, Furie B. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and ligands, PSGL-1. Thromb Haemostas 1995; 74:224-7.
12. Greinacher AB, Potzsch B, Amiral J et al. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992; 67:545-9
13. Amiral J, Bridey F, Vissac M et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95-96.
14. Amiral J, Bridey F, Wolf M et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995; 73:21-28.
15. Amiral J, Marfaingkoka A, Wolf M et al. Presence of autoantibodies to interleukin-8 or neutrophil activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996; 88:410-5.
16. Gerotziafas GT, Lecrubier C, Makris PE, Lecompte E. The role of platelet factor 4 in in vitro platelet activation induced by the antibodies from patients with heparin-induced thrombocytopenia. Thromb Haemost 1995; 73:1064-9.
17. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. New Eng J Med 1987; 316:581-9.
18. Kelton JG, Sheridan D, Santos A et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72:925-30.
19. McCrae KR, Shatill SJ, Cines BD. Platelet activation induces increased Fcγ receptor expression. J Immunol 1990; 144:3920-7.
20. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73:235-40.
21. Engstad CS, Lia K, Rekdal O et al. A novel biological effect of platelet factor 4 (PF4): enhancement of LPS-induced tissue factor activity in monocytes. J Leukoc Biol 1995; 58:575-81.
22. Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB 1994; 8:1296-301.
23. Mendlovic S, Brocke S, Shoenfeld Y et al. Induction of SLE like disease in mice by a common anti-DNA idiotype. Proc Natl Acad Sci USA 1988; 85:2260-4.
24. Blank M, Krup M, Mendlovic S et al. The importance of the pathogenic 16/6 idiotype in the induction of SLE in naive mice. Scan J Immunol 1990; 31:45-52.
25. Blank M, Krause I, Ben-Bassat M, Shoenfeld Y. Induction of experimental antiphospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype. J Autoimmun 1992; 5:1-15.
26. Bakimer R, Fishman P, Blank M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with human monoclonal anti-cardiolipin antibody (H-3). J Clin Invest 1992; 89:1558-63.
27. Cohen J, Bakimer R, Blank M et al. Pathogenic natural anti-cardiolipin antibodies: the experience from monoclonal gammopathy. Clin Exp Immunol 1994; 97:181-6.
28. Tincani A, Balesterieri G, Allegri F et al. Induction of experimental SLE in naive mice by immunization with human polyclonal anti-DNA antibody carrying the 16/6 idiotype. Clin Exp Rheumatol 1994; 11:129-34.
29. Dang H, Noriyoshi C, Takei M et al. Induction of lupus associated autoantibodies by immunization with native and recombinant Ig peptides expressing a cross-reactive idiotype 4B4. J Immunol 1993; 151:7260-7.
30. Rombach E, Steler DA, JC Brown. Rabbits produce SLE like anti-RNA polymerase I and anti-DNA autoantibodies in response to immunization with either human or murine SLE anti-DNA antibodies. Autoimmunity 1992; 13:291-302.
31. Blank M, Tomer Y, Stein M et al. Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Clin Exp Immunol 1995; 102:120-6.
32. Tomer Y, Gilburd B, Blank M et al. Characterization of biologically active ANCA, induced in mice: pathogenic role in experimental vasculitis. Arthritis Rheum 1995; 38:1375-81.
33. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67:27-30.
34. Arepally G, Reynolds C, Tomaski A et al. Sensitivity and specificity of PF4/ ELISA assay in the detection of heparin associated thrombocytopenia/ thrombosis. Am J Clin Pathol 1996 (in press).
35. Shibata S, Harpel PC, Gharavi A et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III - thrombin complexes. Blood 1994; 83:2532-40.
36. Del-Papa N, Guidali L, Spatola L et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: β2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995; 13:179-85.
37. McNeil HP, Simpson RJ, Chesterman CN, Krillis SA. Antiphospholipid antibodies are directed against a complex antigen that includes lipid-binding inhibitor of coagulation β2-glycoprotein I (apolipoproteinH). Proc Natl Acad Sci USA 1990; 87:4120-4.
38. Galli M, Comfurius P, Maasen C et al. Anticardiolipin antibodies (ACA) are directed not to cardiolipin but to plasma protein cofactor. Lancet 1990; 335:1544-7.
39. LeTonque'ze M, Salozhin K, Dueymes M et al. Role of β2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus 1995; 4:179-86.
40. Jerne NK. Towards a network theory of the immune system. Annales D'immunologie 1974; 125c:373-89.
41. Jerne NK, Roland J, Cazenave PA. Recurrent idiotypes and internal images. EMBO 1982; 1:243-7.
42. Pan Y, Stacieann C, Yuhas C, Amzel M. Anti-idiotypic antibodies: biological function and structural studies. FASEB 1995; 9:43-49.
43. Roth C, Somme G, Schiff CJ, Theze J. Immune response against poly (Glu60, ALA30, Tyr10) (GAT): immunization with monoclonal anti-idiotypic antibodies leads to the predominant stimulation of idiotypically similar immunoglobulins with anti-GAT activity. Eur J Immunol 1985; 15:576-80.
44. Dang H, Lazaridis K, Talal N. Induction of autoantibodies in normal BALB/c mice by perturbation of the idiotypic network. Arthritis Rheum 1992; 35: Suppl. 24.
45. Bakimer R, Blank M, Kosashvilli D et al. Anti phospholipid syndrome and the idiotypic network. Lupus 1995; 4:204-8.
46. Fougereau M, Corbet S, Mazza G et al. The GAT system: a possible germ line idiotypic netwrok. In: Reichlin M, Capra JD, eds. Idiotypes. New York: Academic Press, Inc., 1996; 19:3-16.
47. Aster R. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995; 332:1374-6.
48. Hewlett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994; 57:1-127.
49. Indik Z, Pan XQ, Huang MM et al. Insertion of cytoplasmic tyrosine sequences into the nonpagocytic receptor FcRγIIB establishes phagocytic function. Blood 1994; 83:2072-80.
50. Clynes R, Ravetch R. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995; 3:21-26.
51. Warkeritin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-5.
52. Barradas MD, Mikhailidis DP, Epemolu O et al. Comparison of platelet pro-aggregatory effect of conventional unfractionated heparins and low molecular weight heparin fraction (CY 222). Br J Haematol 1987; 67:451-7.